| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with … J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ... Lancet Oncol 16 (5), 499-508, 2015 | 984 | 2015 |
| Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes N Tsavaris, C Kosmas, M Vadiaka, P Kanelopoulos, D Boulamatsis British journal of cancer 87 (1), 21-27, 2002 | 426 | 2002 |
| Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study C Kosmas, MS Kallistratos, P Kopterides, J Syrios, H Skopelitis, ... Journal of cancer research and clinical oncology 134, 75-82, 2008 | 385 | 2008 |
| Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience A Polyzos, N Tsavaris, C Kosmas, T Arnaouti, N Kalahanis, C Tsigris, ... Oncology 61 (2), 129-133, 2001 | 163 | 2001 |
| Predictors of survival in stage IV metastatic colorectal cancer M Zacharakis, ID Xynos, A Lazaris, T Smaro, C Kosmas, A Dokou, ... Anticancer Research 30 (2), 653-660, 2010 | 141 | 2010 |
| A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian … A Polyzos, N Tsavaris, C Kosmas, L Giannikos, M Katsikas, N Kalahanis, ... Oncology 56 (4), 291-296, 1999 | 132 | 1999 |
| Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy C Kosmas, D Snook, CS Gooden, NS Courtenay-Luck, MJ McCall, ... Cancer Research 52 (4), 904-911, 1992 | 132 | 1992 |
| Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell … N Mylonakis, A Athanasiou, N Ziras, J Angel, A Rapti, S Lampaki, N Politis, ... Lung cancer 68 (2), 240-247, 2010 | 129 | 2010 |
| Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study N Tsavaris, C Kosmas, H Skopelitis, P Gouveris, P Kopteridis, D Loukeris, ... Investigational new drugs 23, 369-375, 2005 | 128 | 2005 |
| Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer N Tsavaris, C Kosmas, P Gouveris, K Gennatas, A Polyzos, D Mouratidou, ... Investigational new drugs 22, 193-198, 2004 | 123 | 2004 |
| Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial D Mavroudis, N Malamos, A Alexopoulos, C Kourousis, S Agelaki, E Sarra, ... Annals of oncology 10 (2), 211-216, 1999 | 116 | 1999 |
| Molecular insights into the immunopathogenesis of follicular lymphoma K Stamatopoulos, C Kosmas, C Belessi, N Stavroyianni, P Kyriazopoulos, ... Immunology Today 21 (6), 298-305, 2000 | 92 | 2000 |
| Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy–a survey of 427 patients N Tsavarisabcdef, C Kosmasabcdef, M Vadiakabcdf, M Efremidisbcdf, ... Signature 8 (6), 57, 2002 | 90 | 2002 |
| Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study N Tsavaris, P Kopterides, C Kosmas, A Efthymiou, H Skopelitis, ... Pain Medicine 9 (8), 1209-1216, 2008 | 85 | 2008 |
| Anti-CD20-based therapy of B cell lymphoma: state of the art C Kosmas, K Stamatopoulos, N Stavroyianni, N Tsavaris, T Papadaki Leukemia 16 (10), 2004-2015, 2002 | 84 | 2002 |
| Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer C Kosmas, NB Tsavaris, NA Malamos, M Vadiaka, C Koufos Journal of clinical oncology 19 (1), 119-126, 2001 | 82 | 2001 |
| Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer A Maraveyas, D Snook, V Hird, C Kosmas, CF Meares, HE Lambert, ... Cancer 73 (S3), 1067-1075, 1994 | 73 | 1994 |
| Follicular lymphoma immunoglobulin κ light chains are affected by the antigen selection process, but to a lesser degree than their partner heavy chains K Stamatopoulos, C Kosmas, T Papadaki, E Pouliou, C Belessi, ... British journal of haematology 96 (1), 132-146, 1997 | 72 | 1997 |
| Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis S Sougioultzis, J Syrios, ID Xynos, N Bovaretos, C Kosmas, J Sarantonis, ... European Journal of Surgical Oncology 37 (4), 312-318, 2011 | 67 | 2011 |
| Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis N Papadoniou, C Kosmas, K Gennatas, A Polyzos, D MouratidoU, ... Anticancer research 28 (1B), 543-549, 2008 | 65 | 2008 |
Evangelos FelekourasNational & Kapodistrian University of AthensVerified email at med.uoa.gr
